Emergent Biosolutions
EBS
EBS
134 hedge funds and large institutions have $101M invested in Emergent Biosolutions in 2023 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 46 increasing their positions, 44 reducing their positions, and 46 closing their positions.
New
Increased
Maintained
Reduced
Closed
more ownership
Funds ownership: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less call options, than puts
Call options by funds: $ | Put options by funds: $
less funds holding
Funds holding: →
28% less capital invested
Capital invested by funds: $141M → $101M (-$39.7M)
59% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 46
Holders
134
Holding in Top 10
–
Calls
$443K
Puts
$520K
Top Buyers
| 1 | +$4.47M | |
| 2 | +$3.15M | |
| 3 | +$2.31M | |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$1.56M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$1.49M |
Top Sellers
| 1 | -$3.77M | |
| 2 | -$2.7M | |
| 3 | -$1.87M | |
| 4 |
Squarepoint
New York
|
-$1.22M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$983K |